aCGT Vector are a “Point of Care” Cellular Therapy Company, delivering precision medicines across a multiple hospital-based ATMP (Advanced Therapy Medicinal Product) GMP licensed facility network. The leading Cell Therapy is CAR-T treatment, increasingly approved for reimbursement.
Through its novel approach to integrate and digitally twin patient and PODular “GMP-in-a-POD” distributed manufacturing, it is rolling out across Cancer Centres of Excellence. Commencing in 2021 with its new facility in St. James’s Hospital in Dublin, this is a centre where almost 200 Bone Marrow transplant Cellular procedures take place annually.
aCGT Vector will offer Cell Therapy innovators’ accessible agile, right-sized manufacturing and clinical trial capacity across its network of POD’s. This will allow clinical trials to scale from N=1 (10-20 patient trial) to multiples of N=1 (>20 patient trials) across its multi-POD-centred clinical trials as therapies move along the clinical continuum.
Our ultimate goal is to make cancer history; by increasing accessibility to potentially curative personalised medicines, transforming lives of cancer patients, by giving consultants localised treatment options, and ultimately facilitate a paradigm shift towards distributed end-to-end point-of-care healthcare provision.
We are adapting our PODular approach to bring to market an end to end mRNA and DNA vaccine manufacturing platform using Touchlight’s dbDNA and Cytiva’s Single-use closed system FlexFactory mRNA, LNP to Vanrx fill finish technology within Ireland for broader PODular application across the EU.
Our leadership team
aCGT Vector have assembled a world class team of cellular therapy expertise within major cellular therapy centres of excellence, using state of the art closed-system cellular processing standardisation technology and digitisation loopback platform within a GMP ATMP facility network of PODS located proximal to rare disease patients. aCGT Vector will deliver cellular therapies through co-location of expertise more efficiently with less burden being placed on patients, more safely within centres of excellence, and by bringing more value for payers – through data-driven optimised patient outcomes as a result of carrying out these transformational and potentially curative cellular therapy procedures proximal to patients who are in need and to clinicians with unique rare disease expertise.
aCGT Vector have assembled a world class team of cellular therapy expertise within major cellular therapy centres of excellence, using state of the art closed-system cellular processing standardisation technology and digitisation loopback platform within a GMP ATMP facility network of PODS located proximal to rare disease patients. aCGT Vector will deliver cellular therapies through co-location of expertise more efficiently with less burden being placed on patients, more safely within centres of excellence, and by bringing more value for payers – through data-driven optimised patient outcomes as a result of carrying out these transformational and potentially curative cellular therapy procedures proximal to patients who are in need and to clinicians with unique rare disease expertise.
aCGT Vector’s Vision is that it will facilitate multi-centre delivery of Cellular Therapy Procedures by strategically locating aCGT Vector’s ATMP GMP-in-a-BOX in Cellular Therapy hospital centres of excellence.
It’s our Mission the data from multiple centres that aCGT Vector will securely collect and anonymise, aggregate and closely analyse through its digital platform with its stakeholders.
Tony Holohan joins board of Irish cell therapy company aCGT Vector Founded in 2020, aCGT Vector is a member of the Irish Government-funded Healed Consortium.
The future of the delivery of Development of Cell and Gene Therapies SAN FRANCISCO & DUBLIN–(BUSINESS WIRE)–Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene
The Future of the Delivery of Modern Medicine in St. James’s Hospital and the Trinity College Dublin Clinical Research Facility in Dublin 7-8th July. Thanks
Patients requiring CAR-T immunotherapy previously had to travel to UK for treatment A Co Mayo man has become the first patient in Ireland to receive groundbreaking cell therapy treatment
Allogeneic products may dominate the cell therapy sector thanks to tech and cost advantages but there will always be room for autologous treatments, say experts.
The Road To 50 States! Discovering the Future of Healthcare After achieving what was previously thought impossible – 25 European countries in 25 days –
© aCGT Vector – All Rights Reserved
aCGT Vector DAC,
The Mill Enterprise Hub,
Newtown Link Road,
Greenhills, Drogheda,
Co. Louth, A92 CD3D,
Republic of Ireland,
Europe
+353 864667889